- Home
- CADL
as 03-25-2025 11:31am EST
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | NEEDHAM |
| Market Cap: | 306.4M | IPO Year: | 2021 |
| Target Price: | $21.00 | AVG Volume (30 days): | 918.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.45 - $14.60 | Next Earning Date: | 03-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Candel Therapeutics Inc. (CADL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tak Paul Peter | CADL | Chief Executive Officer | Mar 18 '25 | Sell | $8.89 | 26,172 | $229,624.02 | 226,140 | |
| Barone Francesca | CADL | Chief Scientific Officer | Mar 18 '25 | Sell | $8.76 | 32,146 | $281,672.90 | 96,527 | |
| Nichols William Garrett | CADL | Chief Medical Officer | Mar 18 '25 | Sell | $8.76 | 45,316 | $396,995.35 | 52,493 | |
| Tyagarajan Seshu | CADL | Chief Technology Officer | Mar 17 '25 | Sell | $8.82 | 31,278 | $275,947.03 | 85,512 | |
| Schoch Charles | CADL | See Remarks | Mar 17 '25 | Sell | $8.83 | 5,000 | $44,169.00 | 38,038 | |
| Tyagarajan Seshu | CADL | Chief Technology Officer | Jan 15 '25 | Sell | $7.23 | 14,322 | $103,476.45 | 85,512 | |
| Tak Paul Peter | CADL | Chief Executive Officer | Jan 15 '25 | Sell | $7.23 | 21,704 | $156,811.40 | 226,140 | |
| Barone Francesca | CADL | Chief Scientific Officer | Jan 15 '25 | Sell | $7.23 | 13,534 | $97,783.15 | 96,527 | |
| Nichols William Garrett | CADL | Chief Medical Officer | Jan 15 '25 | Sell | $7.23 | 10,428 | $75,342.30 | 52,493 | |
| Schoch Charles | CADL | See Remarks | Jan 15 '25 | Sell | $7.23 | 9,511 | $68,716.97 | 38,038 |
Latest Candel Therapeutics Inc. News
CADL Breaking Stock News: Dive into CADL Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Candel Therapeutics Partners With IDEA Pharma for CAN-2409 Commercialization
GlobeNewswire
5 days ago
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
GlobeNewswire
7 days ago
Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board
GlobeNewswire
12 days ago
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Simply Wall St.
25 days ago
Institutional investors in Candel Therapeutics, Inc. (NASDAQ:CADL) see US$153m decrease in market cap last week, although long-term gains have benefitted them.
Clinical Trials Arena
a month ago
Candel Therapeutics stock drops despite OS improvement in PDAC trial
MT Newswires
a month ago
Candel Therapeutics Shares Fall After Final Pancreatic Cancer Survival Data
GlobeNewswire
a month ago
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Compare CADL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CADL Candel Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.